Stockscreener 앱 받기
4.445
2.55%
-0.125
전일 마감가:
$4.57
열려 있는:
$4.58
하루 거래량:
2.16M
Relative Volume:
0.64
시가총액:
$597.83M
수익:
-
순이익/손실:
$-217.44M
주가수익비율:
-2.0484
EPS:
-2.17
순현금흐름:
$-205.20M
1주 성능:
+3.81%
1개월 성능:
+115.15%
6개월 성능:
+40.05%
1년 성능:
-17.83%
1일 변동 폭
$4.44
$4.6888
1주일 범위
$3.71
$5.17
52주 변동 폭
$1.11
$5.9499
Prime Medicine Inc Stock (PRME) Company Profile
명칭
Prime Medicine Inc
전화
617-465-0013
주소
60 FIRST ST., CAMBRIDGE
PRME을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
4.445 | 646.25M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.77 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.68 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.58 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
574.06 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
293.99 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-05-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-20 | 개시 | H.C. Wainwright | Buy |
| 2024-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-04-22 | 개시 | Chardan Capital Markets | Buy |
| 2024-04-08 | 개시 | TD Cowen | Buy |
| 2024-04-03 | 개시 | Wedbush | Outperform |
| 2024-01-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-08 | 개시 | Citigroup | Neutral |
| 2023-10-09 | 개시 | BMO Capital Markets | Outperform |
| 2023-07-31 | 개시 | Guggenheim | Buy |
| 2023-04-18 | 개시 | Stifel | Buy |
| 2022-11-14 | 개시 | Goldman | Neutral |
| 2022-11-14 | 개시 | JP Morgan | Overweight |
| 2022-11-14 | 개시 | Jefferies | Buy |
| 2022-11-14 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Prime Medicine Inc 주식(PRME)의 최신 뉴스
Prime Medicine Inc. Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
Is Prime Medicine Inc. a good long term investmentPowerful market insights - jammulinksnews.com
What drives Prime Medicine Inc. stock priceExponential wealth increase - Autocar Professional
What analysts say about Prime Medicine Inc. stockStrong return on assets - Autocar Professional
Prime Medicine(PRME) Shares Soar 10.65% on Analyst Rating, Funding Boost - AInvest
Prime Medicine Surges 18% on Funding Catalyst: Is This the Start of a Biotech Breakout? - AInvest
BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT - MSN
Prime Medicine stock price target reiterated at $6 by JMP on CF funding - Investing.com UK
Prime Medicine (PRME.O) Surges 5.9%: What’s Behind the Intraday Rally? - AInvest
Prime Medicine (PRME): A High-Conviction Biotech Play with a 154% Upside - AInvest
10 Hot Penny Stocks to Invest in Now - Insider Monkey
Cystic Fibrosis Foundation grants new funding to advance development of Prime Medicine’s prime editors - BioWorld MedTech
Prime Medicine, Inc.: Buy Rating Affirmed on Innovative Gene Editing Technology and Strategic Advancements - TipRanks
Prime Medicine stock rating reiterated by H.C. Wainwright on CF partnership - Investing.com Canada
CF Trading Volume Surges 77% to 2.91 Billion, Ranks 364th in Market - AInvest
Prime Editing's Billion-Dollar Gamble: Can Prime Medicine's $24M Boost Cement Dominance in Cystic Fibrosis? - AInvest
Prime Medicine announces additional funding of up to $24M from CF Foundation - TipRanks
Prime Medicine Announces Additional Funding of Up to $24 - GlobeNewswire
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation - citybiz
Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy - Yahoo Finance
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis - The Manila Times
Cystic Fibrosis Foundation expands funding for Prime Medicine By Investing.com - Investing.com Nigeria
Cystic Fibrosis Foundation expands funding for Prime Medicine - Investing.com
CF Foundation Backs Prime Medicine with $24M to Develop Cure for 93% of Cystic Fibrosis Patients - Stock Titan
Prime Medicine chief scientific officer to depart, will serve as consultant - Investing.com Nigeria
Prime Medicine Announces CSO Resignation and Transition - TipRanks
Prime Medicine stock plummets amid restructuring and leadership changes - MSN
Prime Medicine soars as Jones sees it as an acquisition target - MSN
Prime Medicine's Liver Gene Therapy Platform: A Breakthrough in Rare Disease Treatment? - AInvest
Prime Medicine: Pressing Forward With Lead Liver Targeting Indications (NASDAQ:PRME) - Seeking Alpha
Prime Therapeutics stock surges 35% on JonesTrading's acquisition optimism. - AInvest
JonesResearch lists factors for Prime Medicine continued share rally - TipRanks
Prime Medicine stock soars amid gene editing sector momentum By Investing.com - Investing.com Canada
Prime Medicine, Inc.: Buy Rating Driven by Strategic Positioning and Market Momentum - TipRanks
Prime Medicine's Liver Pivot: A Billion-Dollar Leap with Validated Prime Editing - AInvest
Prime Medicine Focuses on Genetic Liver Diseases, Partnered Programs After Positive CGD Data - Insider Monkey
Prime Medicine Inc (PRME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Prime Medicine Inc 주식 (PRME) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Liu David R. | 10% Owner |
Jun 23 '25 |
Buy |
2.16 |
21,000 |
45,402 |
20,219,945 |
| Liu David R. | 10% Owner |
Jun 16 '25 |
Buy |
1.49 |
21,000 |
31,196 |
20,198,945 |
| Liu David R. | 10% Owner |
Jun 11 '25 |
Buy |
1.60 |
21,000 |
33,590 |
20,177,945 |
| Brudnick Richard | Chief Business Officer |
May 20 '25 |
Buy |
1.19 |
20,000 |
23,790 |
20,000 |
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
0.55%
자본화:
|
볼륨(24시간):